Hologic to acquire Biotheranostics, leader in molecular tests for breast and metastatic cancers, for approximately $230 million (Hologic Press Release)
"Hologic, Inc…announced today that it has agreed to acquire Biotheranostics, Inc…for approximately $230 million, subject to working capital and other customary closing adjustments…Both of Biotheranostics’ tests are PCR (polymerase chain reaction)-based gene expression tests that have been extensively validated in large studies in areas of oncology with critical unmet needs and high growth potential. The BCI test is included in several clinical practice guidelines for breast cancer, and both tests enjoy widespread reimbursement in the United States…The acquisition is expected to be slightly dilutive to Hologic’s non-GAAP earnings per share in fiscal 2021, break-even in 2022, and accretive thereafter. The acquisition is expected to close in February of 2021, subject to antitrust clearance and other customary closing conditions."